What is Antibe Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-05-23), Antibe Therapeutics's share price is C$0.295.
Antibe Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.35. Hence, Antibe Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Antibe Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 12 years, Antibe Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 2.11. The lowest was 0.00. And the median was 1.97.
Antibe Therapeutics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was C$-0.07.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.35.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 9.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 16.80% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 16.60% per year.
During the past 12 years, Antibe Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 80.80% per year. The lowest was -128.60% per year. And the median was 9.10% per year.
Antibe Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Antibe Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antibe Therapeutics Price-to-Operating-Cash-Flow Chart
|
Antibe Therapeutics Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Antibe Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Antibe Therapeutics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Antibe Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Antibe Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Antibe Therapeutics's Price-to-Operating-Cash-Flow falls into.
Antibe Therapeutics Price-to-Operating-Cash-Flow Calculation
Antibe Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.295 | / | -0.346 |
| = | |
Antibe Therapeutics's Share Price of today is C$0.295.
Antibe Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Antibe Therapeutics (TSX:ATE) Business Description
Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Antibe Therapeutics (TSX:ATE) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:ATE has been successfully added to your